Logo image of IBT.CA

IBEX TECHNOLOGIES INC (IBT.CA) Stock Fundamental Analysis

TSX-V:IBT - TSX Venture Exchange - CA4489375085 - Common Stock - Currency: CAD

1.44  0 (0%)

Fundamental Rating

6

Taking everything into account, IBT scores 6 out of 10 in our fundamental rating. IBT was compared to 23 industry peers in the Biotechnology industry. IBT gets an excellent profitability rating and is at the same time showing great financial health properties. IBT is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

IBT had positive earnings in the past year.
In the past year IBT had a positive cash flow from operations.
IBT had positive earnings in 4 of the past 5 years.
IBT had a positive operating cash flow in 4 of the past 5 years.
IBT.CA Yearly Net Income VS EBIT VS OCF VS FCFIBT.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1M -1M 2M 3M

1.2 Ratios

IBT has a Return On Assets of 22.64%. This is amongst the best in the industry. IBT outperforms 100.00% of its industry peers.
IBT's Return On Equity of 28.25% is amongst the best of the industry. IBT outperforms 100.00% of its industry peers.
With an excellent Return On Invested Capital value of 6.83%, IBT belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for IBT is significantly below the industry average of 21.12%.
Industry RankSector Rank
ROA 22.64%
ROE 28.25%
ROIC 6.83%
ROA(3y)14.54%
ROA(5y)7.95%
ROE(3y)18.48%
ROE(5y)9.94%
ROIC(3y)9.26%
ROIC(5y)N/A
IBT.CA Yearly ROA, ROE, ROICIBT.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10 -10 20 30

1.3 Margins

IBT has a better Profit Margin (51.82%) than 100.00% of its industry peers.
IBT's Profit Margin has improved in the last couple of years.
IBT's Operating Margin of 19.58% is amongst the best of the industry. IBT outperforms 100.00% of its industry peers.
In the last couple of years the Operating Margin of IBT has grown nicely.
Looking at the Gross Margin, with a value of 71.29%, IBT belongs to the top of the industry, outperforming 88.00% of the companies in the same industry.
IBT's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 19.58%
PM (TTM) 51.82%
GM 71.29%
OM growth 3Y11.49%
OM growth 5YN/A
PM growth 3Y41.01%
PM growth 5YN/A
GM growth 3Y6.79%
GM growth 5Y12.72%
IBT.CA Yearly Profit, Operating, Gross MarginsIBT.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 60

More info and screens

8

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), IBT is creating some value.
Compared to 1 year ago, IBT has less shares outstanding
The number of shares outstanding for IBT remains at a similar level compared to 5 years ago.
The debt/assets ratio for IBT has been reduced compared to a year ago.
IBT.CA Yearly Shares OutstandingIBT.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M
IBT.CA Yearly Total Debt VS Total AssetsIBT.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

2.2 Solvency

IBT has an Altman-Z score of 4.22. This indicates that IBT is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 4.22, IBT belongs to the best of the industry, outperforming 92.00% of the companies in the same industry.
IBT has a debt to FCF ratio of 1.60. This is a very positive value and a sign of high solvency as it would only need 1.60 years to pay back of all of its debts.
IBT has a better Debt to FCF ratio (1.60) than 96.00% of its industry peers.
A Debt/Equity ratio of 0.10 indicates that IBT is not too dependend on debt financing.
IBT has a Debt to Equity ratio (0.10) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF 1.6
Altman-Z 4.22
ROIC/WACC0.89
WACC7.68%
IBT.CA Yearly LT Debt VS Equity VS FCFIBT.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M 10M

2.3 Liquidity

A Current Ratio of 5.08 indicates that IBT has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.08, IBT is in the better half of the industry, outperforming 76.00% of the companies in the same industry.
A Quick Ratio of 4.97 indicates that IBT has no problem at all paying its short term obligations.
IBT has a better Quick ratio (4.97) than 72.00% of its industry peers.
Industry RankSector Rank
Current Ratio 5.08
Quick Ratio 4.97
IBT.CA Yearly Current Assets VS Current LiabilitesIBT.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

4

3. Growth

3.1 Past

IBT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 139.95%, which is quite impressive.
The Earnings Per Share has been growing by 59.15% on average over the past years. This is a very strong growth
Looking at the last year, IBT shows a decrease in Revenue. The Revenue has decreased by -0.82% in the last year.
Measured over the past years, IBT shows a quite strong growth in Revenue. The Revenue has been growing by 9.64% on average per year.
EPS 1Y (TTM)139.95%
EPS 3Y59.15%
EPS 5YN/A
EPS Q2Q%20.09%
Revenue 1Y (TTM)-0.82%
Revenue growth 3Y12.87%
Revenue growth 5Y9.64%
Sales Q2Q%17.51%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IBT.CA Yearly Revenue VS EstimatesIBT.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 9.00, which indicates a very decent valuation of IBT.
Based on the Price/Earnings ratio, IBT is valued cheaper than 100.00% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.54, IBT is valued rather cheaply.
Industry RankSector Rank
PE 9
Fwd PE N/A
IBT.CA Price Earnings VS Forward Price EarningsIBT.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, IBT is valued cheaply inside the industry as 96.00% of the companies are valued more expensively.
92.00% of the companies in the same industry are more expensive than IBT, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 34.47
EV/EBITDA 14.11
IBT.CA Per share dataIBT.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.1 0.2 0.3 0.4 0.5

4.3 Compensation for Growth

IBT has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

IBT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IBEX TECHNOLOGIES INC

TSX-V:IBT (4/5/2024, 7:00:00 PM)

1.44

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)12-15 2021-12-15
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap35.30M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 9
Fwd PE N/A
P/S 4.53
P/FCF 34.47
P/OCF 15.87
P/B 2.47
P/tB 2.47
EV/EBITDA 14.11
EPS(TTM)0.16
EY11.11%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.04
FCFY2.9%
OCF(TTM)0.09
OCFY6.3%
SpS0.32
BVpS0.58
TBVpS0.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 22.64%
ROE 28.25%
ROCE 9.74%
ROIC 6.83%
ROICexc 15.45%
ROICexgc 15.45%
OM 19.58%
PM (TTM) 51.82%
GM 71.29%
FCFM 13.13%
ROA(3y)14.54%
ROA(5y)7.95%
ROE(3y)18.48%
ROE(5y)9.94%
ROIC(3y)9.26%
ROIC(5y)N/A
ROICexc(3y)24.64%
ROICexc(5y)N/A
ROICexgc(3y)24.64%
ROICexgc(5y)N/A
ROCE(3y)13.2%
ROCE(5y)N/A
ROICexcg growth 3Y5.1%
ROICexcg growth 5YN/A
ROICexc growth 3Y5.1%
ROICexc growth 5YN/A
OM growth 3Y11.49%
OM growth 5YN/A
PM growth 3Y41.01%
PM growth 5YN/A
GM growth 3Y6.79%
GM growth 5Y12.72%
F-Score6
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF 1.6
Debt/EBITDA 0.69
Cap/Depr 254.79%
Cap/Sales 15.38%
Interest Coverage 250
Cash Conversion 111.33%
Profit Quality 25.34%
Current Ratio 5.08
Quick Ratio 4.97
Altman-Z 4.22
F-Score6
WACC7.68%
ROIC/WACC0.89
Cap/Depr(3y)113.33%
Cap/Depr(5y)77.81%
Cap/Sales(3y)6.8%
Cap/Sales(5y)4.77%
Profit Quality(3y)120.06%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)139.95%
EPS 3Y59.15%
EPS 5YN/A
EPS Q2Q%20.09%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-0.82%
Revenue growth 3Y12.87%
Revenue growth 5Y9.64%
Sales Q2Q%17.51%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-28.47%
EBIT growth 3Y25.85%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-19.16%
FCF growth 3Y-0.7%
FCF growth 5Y47.39%
OCF growth 1Y42.74%
OCF growth 3Y17.98%
OCF growth 5Y59.75%